journal article·2018-09-10

Design and Biological Assembly of Polyester Beads Displaying Pneumococcal Antigens as Particulate Vaccine

Majela González-Miró, Anna-Maria Radecker, Laura M. Rodríguez-Noda, Mildrey Fariñas-Medina, Caridad Zayas-Vignier, Mabel Hernández-Cedeño, Yohana Serrano, Félix Cardoso, Darielys Santana-Mederos, Dagmar García-Rivera, Yury Valdés-Balbín, Vicente Vérez-Bencomo, Bernd H. A. Rehm

Publisher page

Abstract

Streptococcus pneumoniae can cause life-threatening infections mostly in infants, children, and elderly people. Capsular polysaccharide conjugate vaccines provide serotype-dependent protection against S. pneumoniae infections but fail to protect against new emerging serotypes. To overcome these limitations, pneumolysin (Ply), a serotype-independent and conserved protein was selected. As such subunit vaccines lack immunogenicity, we engineered Ply to be attached to self-assembled polyester beads in order to boost immunogenicity. To display Ply at the surface of these polyester beads, it was translationally fused to the N-terminus of the polyhydroxybutyrate (PHB) synthase (PhaC), which mediates PHB bead assembly inside recombinant Escherichia coli. We also chemically conjugated the capsular polysaccharide (CPS) 19F to isolated PHB beads to further assess their antigen carrier properties. CPS conjugated to soluble tetanus toxoid served as control. Balb/c mice immunized with Ply-PhaC beads and 19F-PhaC beads induced specific and higher IgG levels than the respective soluble counterparts. The induced IgG antibodies recognized Ply in whole cell lysates of six different serotypes of S. pneumoniae. Additionally, restimulated splenocytes from animals immunized with Ply-PhaC beads produced a balanced INF-γ/IL-17A profile unlike animals immunized with soluble Ply. The 19F-PhaC beads induced production of antibodies showing high opsonophagocytic titers against the homologous strain, serotype 19F, while CPS 19F only mixed with PhaC beads did not elicit any detectable immune response. This study provided insight into the design of PHB beads as a carrier of proteinaceous antigens and CPS in order to induce immune responses for the prevention of pneumococcal infections.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Pneumonia and Respiratory Infections · Pneumocystis jirovecii pneumonia detection and treatment · Respiratory viral infections research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Finlay Vaccine Institute, 27th Avenue, No. 19805 between 198 and 202, La Lisa, Havana 11600, Cuba

Institute of Fundamental Sciences, Massey University, Colombo Road, Palmerston North 4422, New Zealand

Centre for Cell Factories and Biopolymers, Griffith Institute for Drug Discovery, Griffith University, Don Young Road, Nathan Campus, Nathan, Queensland 4111, Australia

Funding

Massey University · Griffith University · Finlay Institute, Center for Vaccines Research and Production · MacDiarmid Institute for Advanced Materials and Nanotechnology

References (88)

Show source-provided references
1. 10.1016/S0140-6736(09)61204-610.1016/S0140-6736(09)61204-6 ↗
2. 10.1128/IAI.73.2.1006-1013.200510.1128/IAI.73.2.1006-1013.2005 ↗
3. 10.3390/vaccines201011210.3390/vaccines2010112 ↗
4. 10.1016/S0140-6736(09)61114-410.1016/S0140-6736(09)61114-4 ↗
5. 10.1097/00006454-200003000-0000310.1097/00006454-200003000-00003 ↗
6. 10.1542/peds.106.5.96510.1542/peds.106.5.965 ↗
7. 10.3109/1040841X.2013.81390210.3109/1040841X.2013.813902 ↗
8. 10.1128/IAI.73.3.1304-1312.200510.1128/IAI.73.3.1304-1312.2005 ↗
9. 10.1016/S0264-410X(99)00530-710.1016/S0264-410X(99)00530-7 ↗
10. 10.1146/annurev.mi.47.100193.00051310.1146/annurev.mi.47.100193.000513 ↗
11. 10.1128/IAI.70.6.2886-2890.200210.1128/IAI.70.6.2886-2890.2002 ↗
12. 10.1172/JCI11763110.1172/JCI117631 ↗
13. 10.1074/jbc.M30315120010.1074/jbc.M303151200 ↗
14. 10.1128/IAI.68.2.492-501.200010.1128/IAI.68.2.492-501.2000 ↗
15. 10.1111/j.1365-2958.1991.tb01969.x10.1111/j.1365-2958.1991.tb01969.x ↗
16. 10.1586/14760584.2.2.26910.1586/14760584.2.2.269 ↗
17. 10.1016/j.ajps.2014.06.00210.1016/j.ajps.2014.06.002 ↗
18. 10.1586/14760584.6.5.79710.1586/14760584.6.5.797 ↗
19. 10.2174/15672010677855902910.2174/156720106778559029 ↗
20. 10.1586/erv.10.8910.1586/erv.10.89 ↗
21. 10.1111/sji.1226710.1111/sji.12267 ↗
22. 10.1128/CVI.05505-1110.1128/CVI.05505-11 ↗
23. 10.1038/nrmicro235410.1038/nrmicro2354 ↗
24. 10.1002/bit.26044111010.1002/bit.260441110 ↗
25. 10.21775/cimb.009.04110.21775/cimb.009.041 ↗
26. 10.4161/bioe.1956710.4161/bioe.19567 ↗
27. 10.1128/AEM.03947-1210.1128/AEM.03947-12 ↗
28. 10.1128/CVI.00687-1510.1128/CVI.00687-15 ↗
29. 10.1016/j.vetimm.2013.04.00210.1016/j.vetimm.2013.04.002 ↗
30. 10.1128/AEM.01965-0910.1128/AEM.01965-09 ↗
31. 10.1016/j.heliyon.2017.e0029110.1016/j.heliyon.2017.e00291 ↗
32. 10.1021/acsbiomaterials.6b0035510.1021/acsbiomaterials.6b00355 ↗
33. 10.1038/srep4160710.1038/srep41607 ↗
34. 10.1038/s41598-018-20205-710.1038/s41598-018-20205-7 ↗
35. 10.1021/bc700347310.1021/bc7003473 ↗
36. 10.1128/IAI.06348-1110.1128/IAI.06348-11 ↗
37. 10.1074/jbc.M110.19114810.1074/jbc.M110.191148 ↗
38. 10.1016/j.femsle.2005.05.02710.1016/j.femsle.2005.05.027 ↗
39. 10.1042/bj2003043110.1042/bj20030431 ↗
40. Thompson, T.; Rehm, B. H.; Herbert, A. B.; Saravolac, E. G. Compositions for separation methods. WO/2012/077080, 2012.
41. Thompson, T.; Rehm, B. H. A.; Herbert, A. B.; Saravolac, E. G.; McDermott, P. B.; Draper, J. L. Compositions for separation methods. WO 2013/190453A2, 2013.
42. 10.1007/8623_2014_3410.1007/8623_2014_34 ↗
43. Pierce BCA Protein Assay Kit, 2013 See the following: https://www.thermofisher.com/order/catalog/product/23225.
44. World Health Organization (WHO). Recommendations to assure the quality, safety and efficacy of pneumococcal conjugate vaccines, WHO technical report series; WHO: Geneva, Switzerland, 2009; Vol. 927.
45. 10.1128/IAI.72.12.7115-7123.200410.1128/IAI.72.12.7115-7123.2004 ↗
46. Lowry O. H. · J. Biol. Chem. · 1951 · 193 · 26510.1016/S0021-9258(19)52451-6 ↗
47. 10.1021/ac60111a01710.1021/ac60111a017 ↗
48. Brandl H. · Appl. Environ. Microbiol. · 1988 · 54 · 197710.1128/aem.54.8.1977-1982.1988 ↗
49. 10.1016/j.pep.2011.02.01310.1016/j.pep.2011.02.013 ↗
50. Sambrook J. · 1989
51. 10.1021/ac200812d10.1021/ac200812d ↗
52. de los Toyos J. R. · Infect. Immun. · 1996 · 64 · 48010.1128/iai.64.2.480-484.1996 ↗
53. Werno, A. M. Development of improved diagnostic testing methods for invasive pneumococcal disease. Ph.D. thesis, University of Otago, Dunedin, New Zealand, 2013.
54. McCool T. L. · Infect. Immun. · 1999 · 67 · 486210.1128/IAI.67.9.4862-4869.1999 ↗
55. 10.1172/JCI10966810.1172/JCI109668 ↗
56. Romero-Steiner S. · Clin. Diagn. Lab. Immunol. · 1997 · 4 · 41510.1128/cdli.4.4.415-422.1997 ↗
57. 10.1099/00221287-138-2-24910.1099/00221287-138-2-249 ↗
58. 10.1016/S0008-6215(00)86108-X10.1016/S0008-6215(00)86108-X ↗
59. 10.1016/S0008-6215(00)84638-810.1016/S0008-6215(00)84638-8 ↗
60. 10.1139/v80-16710.1139/v80-167 ↗
61. Virolainen A. · Clin. Diagn. Lab. Immunol. · 1995 · 2 · 70410.1128/cdli.2.6.704-707.1995 ↗
62. 10.1371/journal.ppat.100119110.1371/journal.ppat.1001191 ↗
63. 10.1021/bm801394s10.1021/bm801394s ↗
64. 10.1016/j.copbio.2017.03.01810.1016/j.copbio.2017.03.018 ↗
65. 10.1186/s12934-015-0241-510.1186/s12934-015-0241-5 ↗
66. 10.4049/jimmunol.173.5.314810.4049/jimmunol.173.5.3148 ↗
67. 10.1016/j.biomaterials.2007.08.01510.1016/j.biomaterials.2007.08.015 ↗
68. 10.1016/j.ijpharm.2005.03.03510.1016/j.ijpharm.2005.03.035 ↗
69. 10.1016/j.imlet.2017.05.00310.1016/j.imlet.2017.05.003 ↗
70. Kanclerski K. · J. Clin Microbiol. · 1988 · 26 · 9610.1128/jcm.26.1.96-100.1988 ↗
71. 10.1016/0888-0786(90)90058-V10.1016/0888-0786(90)90058-V ↗
72. 10.1128/IAI.01103-0610.1128/IAI.01103-06 ↗
73. 10.1128/IAI.72.5.2689-2697.200410.1128/IAI.72.5.2689-2697.2004 ↗
74. Rubins J. B. · Infect. Immun. · 1997 · 65 · 297510.1128/iai.65.7.2975-2977.1997 ↗
75. 10.1016/j.micinf.2006.12.00310.1016/j.micinf.2006.12.003 ↗
76. 10.1016/j.chom.2011.01.00710.1016/j.chom.2011.01.007 ↗
77. 10.1073/pnas.112138310910.1073/pnas.1121383109 ↗
78. 10.1172/JCI3673110.1172/JCI36731 ↗
79. 10.1016/j.immuni.2009.08.00110.1016/j.immuni.2009.08.001 ↗
80. González N. · MEDICC Rev. · 2015 · 17 · 3210.37757/MR2015.V17.N4.7 ↗
81. 10.1590/S0001-3765200500020000910.1590/S0001-37652005000200009 ↗
82. 10.1016/S1473-3099(05)01280-610.1016/S1473-3099(05)01280-6 ↗
83. 10.1016/S0264-410X(03)00025-210.1016/S0264-410X(03)00025-2 ↗
84. 10.1016/j.vaccine.2011.09.07810.1016/j.vaccine.2011.09.078 ↗
85. 10.4172/2329-6887.100026110.4172/2329-6887.1000261 ↗
86. 10.1128/CDLI.8.2.363-369.200110.1128/CDLI.8.2.363-369.2001 ↗
87. World Health Organization (WHO). Recommendations for the production and control of pneumococcal conjugate vaccines, WHO technical report series; WHO: Geneva, Switzerland, 2005; Vol. 927, pp 64–98.
88. Plikaytis B. D. · J. Clin. Microbiol. · 2000 · 38 · 204310.1128/JCM.38.6.2043-2050.2000 ↗